News

 

BioStock Life Science Summit , June 9th 2022

Kommuniké från årsstämma i Iconovo

Interim Report for Q1 2022 available in English

The abbreviated Interim Report for January to March 2022 is now avaialble in English. Read it here

Iconovo and Galenica enters a strategic collaboration for the development of new inhalation products

Iconovo has entered into a strategic collaboration with Galenica AB – a company specializing in the development and manufacture of pharmaceuticals…

Quarterly Report for Q1 2022 released

The Quarterly Report for Q1 2022 was released today and is available here, in Swedish.

Meet Iconovo at RDD, Orlando

A team from Iconovo will visit RDD, Respiratory Drug Delivery in beginning of May, in Orlando. There will be an exhibition from Iconovo with inhalation…

Presentation från Erik Penser Bank Health Care Day

Roger Lassing, VP Business Development  på Iconovo, presenterade företaget på Erik Penser Hetlh Care Day den 24 februari 2022 och presentationen…

Iconovo Q4-2021 quarterly report

Significant progress in Iconovo’s three strategic business areas Significant events 1 October – 31 December Iconovo signed an agreement…

Covid-19 nasal vaccine ready for clinical studies

Last week, Iconovo’s partner ISR received the reviewed and approved toxicology report that examined the company's vaccine for intranasal…